"Using data from over 18,000 patients, scientists have identified more than two dozen genetic risk factors involved in Parkinson's disease, including six that had not been previously reported. The study, published in Nature Genetics, was partially"...
Patients should be advised of the possible need to reduce levodopa dosage after the initiation of ELDEPRYL (selegiline hcl) therapy.
Patients (or their families if the patient is incompetent) should be advised not to exceed the daily recommended dose of 10 mg. The risk of using higher daily doses of selegiline should be explained, and a brief description of the 'cheese reaction' provided. Rare hypertensive reactions with selegiline at recommended doses associated with dietary influences have been reported.
Consequently, it may be useful to inform patients (or their families) about the signs and symptoms associated with MAOI induced hypertensive reactions. In particular, patients should be urged to report, immediately, any severe headache or other atypical or unusual symptoms not previously experienced.
Last reviewed on RxList: 7/15/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Eldepryl Information
Report Problems to the Food and Drug Administration
Get breaking medical news.